510(k) device
Urocross Expander System (UES-2018-C1)
Prodeon Medical, Inc. · Temporarily-Placed Urethral Opening System For Symptoms Of Benign Prostatic Hyperplasia (QKA, Class II) · First FDA decision Mar 12, 2026, newest Jun 22, 2026Enlarged prostate (BPH)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
1
Naming "Urocross Expander"
MAUDE reports
0
Brand "Urocross Expander", since 2015
PubMed studies
3
Mentioning "Urocross Expander"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Urocross Expander System (UES-2018-C1)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K261342 · Decided Jun 22, 2026 · 60 days after receipt
Device type: Temporarily-Placed Urethral Opening System For Symptoms Of Benign Prostatic Hyperplasia (QKA) · GI, Urology & Nephrology
K253525 · Decided Mar 12, 2026 · 119 days after receipt
Device type: Temporarily-Placed Urethral Opening System For Symptoms Of Benign Prostatic Hyperplasia (QKA) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)Local determinationIn effectL38378CGS Administrators, LLCUpdated Mar 25, 2026
- PSA (Addition of ICD-9-CM 600.21, Benign localized hyperplasia of prostate with urinary obstruction as a covered indication)Coding analysisReview closedCAG-00332NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Urocross Expander", any status and sponsor, newest update first.
- Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval SheathPivotal-lookingActive, not recruiting
Prodeon Medical, IncNot on our public-company list
NCT05400980 · 240 participants (planned) · Start Jul 5, 2022 · Primary completion Jan 2027
Device: Urocross implant · For: Benign Prostatic Hyperplasia
Sites: Maywood, Illinois; Roanoke, Virginia
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Urocross Expander", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QKA
22 reports: 0 malfunction, 22 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Urocross Expander"[tiab]. The summary above synthesizes these.
- The EXPANDER-1 trial: introduction of the novel Urocrossࡊ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Woo HH, Huang CP, Huang WJ, et al. · Prostate Cancer Prostatic Dis · 2022Clinical Trial, Research Support, Non-U.S. Gov't
- Characterization of a Novel Implant Intended to Expand and Reshape the Prostatic Urethra for the Treatment of Benign Prostatic Hyperplasia: A Pre-Clinical Feasibility Study in the Canine Model.
Chughtai B, Punyala A, Lata SS, et al. · Urology · 2022
- Minimally invasive techniques in quest of Holy Grail of surgical management of enlarged prostates: a narrative review.
Porto JG, Titus R, Camargo F, et al. · World J Urol · 2024Review
Other devices of this type
Also filed under product code QKA.
- iTind SystemMedi-Tate , Ltd. · De Novo 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.